SAN DIEGO, Dec. 12, 2014 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) announced that two scientific
poster presentations on the pharmacology of PEGPH20 will be made at
the 37th Annual San Antonio Breast Cancer Symposium
(SABCS) today. The first of the presentations includes preclinical
data showing that treatment of tumors with PEGPH20 enhances the
action of immune-based cancer therapy such as monoclonal antibodies
(mAbs). The second presentation includes additional supportive
preclinical information on the utility of hyaluronan (HA) as a
potential biomarker for cancer treatments. PEGPH20 is an
investigational PEGylated form of rHuPH20 under development by
Halozyme. PEGPH20 degrades the hyaluronan coating that may provide
a supportive environment in many solid tumors.
SABCS Poster Presentation Details
Title: "Hyaluronan Depletion Sensitizes HAhigh
Tumors to Antibody-Dependent Cell-Mediated Cytotoxicity"
Poster Session: P5-04-02, December
12, 2014, 7:00AM - 7:00PM
CDT
Location: Exhibit Hall A-B
Summary: About 50% of HER2+3 breast cancers and
12% of ovarian cancers accumulate abundant HA in the tumor
microenvironment. The accumulation of HA is known to result in
decreased access of therapeutics to the tumor. Therefore, HA
accumulation may contribute to trastuzumab resistance. When HA is
depleted by treatment with PEGPH20 in vitro,
HAhigh/HER2+3 cells become much more
sensitive to antibody-mediated cellular cytotoxicity. Additionally,
HAhigh/HER2+3 human tumors in mice treated
with PEGPH20 increased the access of trastuzumab and immune cells
to the tumor, resulting in enhanced antitumor activity. These
results suggest that co-administration of PEGPH20 could enhance the
efficacy of trastuzumab in HAhigh/HER2+3
tumors.
Title: "Naked Mole Rat HAS2 and Hyaluronan Are Not Tumor
Suppressive in Human Tumor Xenografts"
Poster Session: P4-04-25, December
12, 2014, 7:00AM - 7:00PM
CDT
Location: Exhibit Hall A-B
Summary: Published third-party literature suggests
that naked mole rat hyaluronan synthase 2 (nmrHAS2) produces
extraordinarily high molecular weight HA, which has tumor
suppressive effects. Transfection of the nmrHAS2 gene into human
tumor cells did not suppress the growth of human tumors in nude
mice and suggests that HA in the naked mole rat may have different
functions than in human cancer, where HA accumulation promotes
tumor growth.
About Halozyme
Halozyme Therapeutics is a
biopharmaceutical company dedicated to developing and
commercializing innovative products that advance patient care. With
a diversified portfolio of enzymes that target the extracellular
matrix, the company's research focuses primarily on a family of
human enzymes, known as hyaluronidases, which increase the
dispersion and absorption of biologics, drugs and fluids.
Halozyme's pipeline addresses therapeutic areas, including
oncology, diabetes and dermatology that have significant unmet
medical need today. The company markets Hylenex®
recombinant (hyaluronidase human injection) and has partnerships
with Roche, Pfizer and Baxter. Halozyme is headquartered in San
Diego. For more information on how we are innovating, please
visit our corporate website at www.halozyme.com.
Safe Harbor Statement
In addition to historical
information, the statements set forth above include forward-looking
statements (including, without limitation, statements concerning
the possible activity, benefits and attributes of PEGPH20, the
possible method of action of PEGPH20, its potential application to
improve cancer therapies and statements concerning future actions
relating to the development of PEGPH20) that involve risk and
uncertainties that could cause actual results to differ materially
from those in the forward-looking statements. The forward-looking
statements are typically, but not always, identified through use of
the words "believe," "enable," "may," "will," "could," "intends,"
"estimate," "anticipate," "plan," "predict," "probable,"
"potential," "possible," "should," "continue," and other words of
similar meaning. Actual results could differ materially from the
expectations contained in forward-looking statements as a result of
several factors, including unexpected expenditures and costs,
unexpected results or delays in development and regulatory review,
regulatory approval requirements, unexpected adverse events and
competitive conditions. These and other factors that may result in
differences are discussed in greater detail in Halozyme's Quarterly
Report on Form 10-Q filed with the Securities and Exchange
Commission on November 10, 2014.
Investor Contact:
Schond Greenway
Halozyme Therapeutics
858-704-8352
ir@halozyme.com
Media Contact:
Susan Neath
Francis
212-301-7182
sfrancis@wcgworld.com
Logo -
http://photos.prnewswire.com/prnh/20100302/LA63139LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/halozyme-announces-presentations-of-preclinical-data-at-the-san-antonio-breast-cancer-symposium-annual-meeting-300008905.html
SOURCE Halozyme Therapeutics, Inc.